Robert G Rowe

US Patent:

6983176, Jan 3, 2006

Filed:

Apr 11, 2001

Appl. No.:

09/832608

Inventors:

Craig Gardner - Brookline MA, US
Michael J. Haass - Albuquerque NM, US
Robert K. Rowe - Corrales NM, US
Howland Jones - Edgewood NM, US
Steven T. Strohl - Cedar Crest NM, US
Matthew J. Novak - Tucson AZ, US
Russell E. Abbink - Albuquerque NM, US
David Nuñez - Sandia Park NM, US
William Gruner - Edgewood NM, US
Robert D. Johnson - Albuquerque NM, US

Assignee:

Rio Grande Medical Technologies, Inc. - Albuquerque NM

International Classification:

A61B 5/00

US Classification:

600310, 600473, 600476

Abstract:

Systems and methods for establishing and/or maintaining the prediction capability over time of a multivariate calibration model designed for quantitative optical spectroscopic measurement of attributes or analytes in bodily tissues, bodily fluids or other biological samples, which are particularly useful when the spectral absorbance of the attribute or analyte is small relative to the background. The present invention provides an optically similar reference sample to capture the characteristics of instrument and environmental variation and to reduce the effect of such variation on the measurement capability of the model. The optically similar reference is preferably stable over time and is designed such that its optical properties are sufficiently matched to the sample of interest that instrument and environmental variations are captured in the same manner in both the test sample of interest and the optically similar reference sample. The optically similar reference sample may include one or more physical components which are spectroscopically measured in a manner which closely mimics the spectroscopic measurement of the test sample of interest. Spectral similarity may also be achieved by using alternative components with spectral characteristics similar to the components contained in the test sample of interest.

US Patent:

20050007582, Jan 13, 2005

Filed:

Jul 7, 2004

Appl. No.:

10/886941

Inventors:

Philippe Villers - Concord MA, US
Robert Rowe - Corrales NM, US
Kristin Nixon - Albuquerque NM, US
Karen Unruh - Albuquerque NM, US

Assignee:

Lumidigm, Inc. - Albuquerque NM

International Classification:

G01N021/55

US Classification:

356300000

Abstract:

Methods and apparatus are provided for collecting optical data. Light is propagated through a reference sample from a source of light to a detector of light to produce a measured reference spectral distribution. Light is also propagated through a subject sample from the source of light to the detector of light to produce a measured subject spectral distribution. At least one of an intensity change and a wavelength shift between the measured reference spectral distribution and a stored reference spectral distribution is identified. The measured subject spectral distribution is compared with a stored subject spectral distribution associated with the stored reference spectral distribution. Such comparison includes accounting for the identified one of the intensity change and the wavelength shift.

US Patent:

20090258006, Oct 15, 2009

Filed:

Apr 8, 2009

Appl. No.:

12/420649

Inventors:

STEPHEN WEISS - ANN ARBOR MI, US
ROBERT G. ROWE - ANN ARBOR MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - ANN ARBOR MI

International Classification:

A61K 39/395
A61K 31/7088
C12Q 1/02

US Classification:

4241301, 435 29, 514 44 R

Abstract:

The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A reduction in nuclear architecture organization identifies an agent that inhibits neovascularization.

US Patent:

44575602, Jul 3, 1984

Filed:

Jan 7, 1982

Appl. No.:

6/337782

Inventors:

Robert L. Rowe - Saline MI
Kenneth W. Christensen - Southfield MI

Assignee:

General Motors Corporation - Detroit MI

International Classification:

B06B 706

US Classification:

301 37P

Abstract:

A hubcap comprises an outer plastic hubcap element and an inner metal retention element secured together. The retention element includes retention tabs, circumferentially spaced, which are disposed in apertures of the plastic hubcap element, the apertures matching the pattern of the wheel fasteners. When the hubcap is installed, the wheel fasteners are disposed in the apertures with the retention tabs engaging the wheel fasteners to retain the hubcap in the installed position.

US Patent:

20140186369, Jul 3, 2014

Filed:

Feb 28, 2014

Appl. No.:

14/194007

Inventors:

- Ann Arbor MI, US
Robert G. Rowe - Ann Arbor MI, US

Assignee:

The Regents of The University of Michigan - Ann Arbor MI

International Classification:

C07K 16/22
A61K 38/16
G01N 33/50
A61K 38/39

US Classification:

4241581, 514 44 R, 514 93, 435 29, 435 61

Abstract:

The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A reduction in nuclear architecture organization identifies an agent that inhibits neovascularization.